MAPT and Alzheimer disease: This MTL tau and neurodegenerative pathology may be responsible for transitioning APOE4 and BCHE-K carriers into AD at an earlier age with less global tau and neurodegenerative pathology (Table 2; Fig. 4) [84, 85].